HealthManagement, Volume 3 - Issue 1, 2009
The pharmaceutical company Boehringer Ingelheim again posted gratifying growth in local currency (+8.3 percent) over the previous year in the first six months of 2009. Consolidated in euro, this reflected growth of + 15.7 percent thanks to the positive exchange rates, with net sales of 6,388 euros million compared with 5,522 million euros in the first six months of the previous year.
The operating income developed equally well over the previous year. Currency effects played their part here, too, adding to the positive development of the individual businesses.
In the first six months, net sales of Boehringer Ingelheim again outpaced the growth on the world pharma market. Boehringer Ingelheim is again expecting sales growth in local currency in the year as a whole to outpace the world pharma market; for the tenth time in succession. Growth in euro depends greatly on the exchange rate trends of the US dollar and the Japanese yen.
